Table 1.
Correlation analysis between TLS presence and maturity and clinicopathological features of EMPD patients.
| Presence | TLS maturity | TLS maturity | |||||||
|---|---|---|---|---|---|---|---|---|---|
| TLS (n = 97) |
No TLS (n = 74) |
P*/OR | Immature TLS (n = 81) |
No TLS (n = 74) |
P*/OR | Mature TLS (n = 16) |
No TLS (n = 74) |
P*/OR | |
| Age, n (%) | .37/1.52 | .34/1.59 | 1$/1.22 | ||||||
| ≥60 | 87 (90) | 63 (85) | 73 (90) | 63 (85) | 14 (86) | 63 (85) | |||
| <60 | 10 (10) | 11 (15) | 8 (10) | 11 (15) | 2 (14) | 11 (15) | |||
| Sex, n (%) | .94/1.04 | .82/1.11 | .99$/0.76 | ||||||
| Male | 83 (86) | 63 (85) | 70 (86) | 63 (85) | 13 (81) | 63 (85) | |||
| Female | 14 (14) | 11 (15) | 11 (14) | 11 (15) | 3 (19) | 11 (15) | |||
| Location, n (%) a | |||||||||
| Scrotum | 86 (89) | 62 (84) | .35/1.51 | 71 (88) | 62 (84) | .49/1.37 | 15 (94) | 62 (84) | .53$/2.90 |
| Armpit | 1 (1) | 6 (8) | .054$/0.12 | 1 (1) | 6 (8) | .10$/0.14 | 0 (0) | 6 (8) | .53$/N/A |
| Perianal | 7 (7) | 5 (7) | .91/1.07 | 6 (7) | 5 (7) | .88/1.10 | 1 (6) | 5 (7) | 1$/0.92 |
| Other sites | 3 (3) | 1 (1) | .81$/2.33 | 3 (4) | 1 (1) | .68$/2.81 | 0 (0) | 1 (1) | 1#/N/A |
| Clinical findings, n (%) | |||||||||
| Erythema | 92 (95) | 72 (97) | .68$/0.51 | 78 (96) | 72 (97) | 1$/0.72 | 14 (86) | 72 (97) | .14#/0.19 |
| No erythema | 5 (5) | 2 (3) | 3 (4) | 2 (3) | 2 (14) | 2 (3) | |||
| Erosions | 36 (37) | 36 (49) | .13/0.62 | 30 (37) | 36 (49) | .14/0.62 | 6 (38) | 36 (49) | .42/0.63 |
| No erosions | 61 (63) | 38 (51) | 51 (63) | 38 (51) | 10 (62) | 38 (51) | |||
| Ulcers | 7 (7) | 7 (9) | .60/0.74 | 5 (6) | 7 (9) | .44/0.63 | 2 (14) | 7 (9) | 1$/1.37 |
| No ulcers | 90 (93) | 67 (81) | 76 (94) | 67 (81) | 14 (86) | 67 (81) | |||
| Hypopigmentation | 26 (27) | 15 (20) | .32/1.44 | 23 (28) | 15 (20) | .24/1.56 | 3 (19) | 15 (20) | 1$/0.91 |
| No hypopigmentation | 71 (73) | 59 (80) | 58 (72) | 59 (80) | 13 (81) | 59 (80) | |||
| Nodules | 8 (8) | 7 (9) | .78/0.86 | 5 (6) | 7 (9) | .44/0.63 | 3 (19) | 7 (9) | .53$/2.21 |
| No nodules | 89 (92) | 67 (91) | 76 (94) | 67 (91) | 13 (81) | 67 (91) | |||
| Primary/Secondary, n (%) | .06/0.37 | .16/0.46 | .02*$/0.16 | ||||||
| Primary | 81 (84) | 69 (93) | 70 (86) | 69 (93) | 11 (69) | 69 (93) | |||
| Secondary | 16 (16) | 5 (7) | 11 (14) | 5 (7) | 5 (31) | 5 (7) | |||
| Subjective symptom, n (%) b | |||||||||
| Only Itching | 55 (57) | 51 (69) | .33/0.59 | 47 (58) | 51 (69) | .28/0.55 | 8 (50) | 51 (69) | 1#/0.94 |
| Only pain | 22 (23) | 13 (18) | .90/0.92 | 17 (21) | 13 (18) | .70/0.78 | 5 (31) | 13 (18) | .85$/2.31 |
| Itching and pain | 9 (9) | 4 (5) | 1$/1.23 | 7 (9) | 4 (5) | 1$/1.05 | 2 (13) | 4 (5) | .88$/3.00 |
| No subjective symptoms | 11 (11) | 6 (8) | 10 (12) | 6 (8) | 1 (6) | 6 (8) | |||
| Tumor In situ or invasive tumor, n (%) | .15/0.61 | .35/0.71 | .06$/0.30 | ||||||
| in situ | 65 (67) | 57 (77) | 57 (70) | 57 (77) | 8 (50) | 57 (77) | |||
| Invasion | 32 (33) | 17 (23) | 24 (30) | 17 (23) | 8 (50) | 17 (23) | |||
| Appendicular involvement, n (%) | .16/1.59 | .24/1.51 | .31$/2.10 | ||||||
| Yes | 36 (37) | 20 (27) | 29 (36) | 20 (27) | 7 (44) | 20 (27) | |||
| No | 61 (63) | 54 (73) | 52 (64) | 54 (73) | 9 (56) | 54 (73) | |||
| Initial/recurrence, n (%) | .06/0.51 | .14/0.58 | .04*$/0.28 | ||||||
| Initial | 63 (65) | 58 (78) | 55 (68) | 58 (78) | 8 (50) | 58 (78) | |||
| Recurrence | 34 (35) | 16 (22) | 26 (32) | 16 (22) | 8 (50) | 16 (22) | |||
| Vascular/lymphatic infiltration, n (%) | .48/1.36 | .52/1.34 | .88$/1.48 | ||||||
| Yes | 17 (18) | 10 (14) | 14 (17) | 10 (14) | 3 (19) | 10 (14) | |||
| No | 80 (82) | 64 (86) | 67 (83) | 64 (86) | 13 (81) | 64 (86) | |||
| Depth of invasion, n (%) | n = 32 | n = 17 | .16/2.36 | n = 24 | n = 17 | .50/1.55 | n = 8 | n = 17 | .05*$/12.83 |
| ≤4mm | 18 (56) | 6 (35) | 11 (46) | 6 (35) | 7 (88) | 6 (35) | |||
| >4mm | 14 (44) | 11 (65) | 13 (54) | 11 (65) | 1 (12) | 11 (65) | |||
P values based on chi square unless otherwise specified.
$ P-value based on Continuity correction chi square test.
# P-value based on Fisher’s exact.
OR, Odds Ratio.
a
The control group was all the onset sites except the experimental group.
b
The control group was the non-subjective symptom group.
*P ≤ 0.05.